Zevra Therapeutics’ Post

Don't forget to register your attendance to the FREE Webinar with MarketOpen Australia that is being held tomorrow, Wednesday 24th July over Zoom. Dr Liz Dallimore will be providing an update on our Phase 2 clinical trial program. Learn more through the post below ⬇️ #AGN #ASX #stroke #clinicaltrial #strokeawareness #lifescience #investorupdate

We have officially dosed our first patient in the Zucara Therapeutics Inc. ZONE study. Grateful to be able to do such groundbreaking work for the #Type1Diabetes community as we attempt to eliminate #hypoglycemia. Dr. Alex Abitbol, who previously evaluated ZT-01 in a Phase 1b study and will be a principal investigator for ZONE, commented, "The positive results from the proof-of-concept Phase 1b study of ZT-01 were intriguing: in addition to observing a rise in glucagon, we also saw a corresponding rise in glucose during hypoglycemia. This suggests that ZT-01 can prevent nocturnal hypoglycemia, which is what we aim to confirm in the ZONE trial." Read more about this landmark study here: https://lnkd.in/gN48gNr5 #clinicalresearch #clinicaltrials #revolutionizingresearch

SFA Therapeutics will be presenting at the BioFuture Conference, in NYC on October 5th at 10:45am Dr. Ira Spector, CEO, will be presenting the updated data from the extension to Cohort 1 of the ongoing Phase 1b clinical trial. The data are summarized below: 92% of patients showed PASI >50 improvement 71% of patients showed PASI >75 improvement 72% is mean PASI improvement in all subjects 87% is mean PASI improvement in subjects with PASI >75

Exciting News! Our CEO, Janet Qi, was recently featured in a Clinical Leader article discussing the FDA advisory committee's critique of Lykos Therapeutics' MDMA studies. Despite the 9-2 vote against the validity of MDMA-assisted therapy trials, this highlights the crucial need for rigorous and well-designed clinical trials in the psychedelic field. At PurMinds, we remain committed to advancing the scientific and clinical understanding of psychedelic compounds. Our focus on meticulous research and innovative formulations, such as our proprietary psilocybin and non-hallucinogenic novel chemical entities, drives us forward. We believe in the potential of psychedelics to revolutionize neurological care and are steadfast in our pursuit of evidence-based therapies. Read the full article to learn more about our perspectives and the future of psychedelic clinical research: link in comments! #PurMinds #Psychedelics #MentalHealth #ClinicalResearch #Innovation #FDA #MDMA #PTSD

Happy World Theranostics Day! At AtomVie Global Radiopharma (AtomVie), we are passionate about transforming patients' lives with high-quality radiopharmaceuticals. Theranostics combine therapeutics and diagnostics, offering personalized treatment and marking a significant milestone in modern healthcare. Tap the 'like' button if you're excited about the future of theranostics, and feel free to share your experiences or questions in the comments below. Let's raise awareness and embrace the growing field of theranostics together! #WorldTheranosticsDay #AtomVieGlobalRadiopharma #Radiopharmaceuticals #NuclearMedicine #PersonalizedMedicine

Discounts for the Neuromodulation Summit 2024 expire this Friday! 📢 Check out the full event guide now: https://ter.li/rw1ht3 This exclusive conference is industry’s must-attend meeting to join the community of 80 experts in neuromodulation to share crucial insights into: ✅ How the CDRH is accelerating patient access to innovation ✅ How to overcome regulatory and clinical challenges to receive funding ✅ How the adoption of invasive and non-invasive devices differs ✅ How to choose which submission type is the best first step Joined by the likes of FDA, LivaNova, Axonics, Inc., Cognito Therapeutics, Inc., Neuspera Medical Inc., ClearPoint Neuro, Inc. and many more - this is not one to miss! Save up to $400 on your pass and join them in Boston this June: https://ter.li/wummg3

Headed home from the 15th International Congress, after 2 full days of interesting and innovative presentations! The future is getting much brighter for patients with MPN, with many novel new therapeutics on the horizon! #MPN #clinicaltrials #patientsfirst

We invite you to watch the latest US HAEA Treatment Education Webinar Brief: Astria's ALPHA-STAR Clinical Trial of potential therapy STAR-0215 with Chris Morabito, M.D., CMO at Astria Therapeutics. Learn more about available HAE treatments and/or clinical development efforts. Watch the webinar HERE: https://lnkd.in/gEAwgYeX #HAE #HAEA #WebinarBrief #HereditaryAngioedema